n-(2-hydroxypropyl)methacrylamide has been researched along with deoxycytidine in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hennink, WE; Huber, PE; Lammers, T; Peschke, P; Storm, G; Subr, V; Ulbrich, K | 1 |
Cheney, DL; Ghandehari, H; Kopeček, J; Larson, N; Ray, A; Yang, J | 1 |
Buckway, B; Ghandehari, H; Ray, A; Wang, Y | 1 |
Kopeček, J; Sima, M; Yang, J; Zhang, R; Zhou, Y | 1 |
Fang, Y; Kopeček, J; Li, Y; Pan, H; Yang, J; Zhang, L; Zhang, R | 1 |
Chen, K; Dai, Y; Gong, Q; Luo, K; Ma, X; Tang, JZ; Zhang, Y | 1 |
6 other study(ies) available for n-(2-hydroxypropyl)methacrylamide and deoxycytidine
Article | Year |
---|---|
Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers.
Topics: Acrylamides; Animals; Antineoplastic Agents; Apoptosis; Biocompatible Materials; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Male; Materials Testing; Molecular Structure; Neoplasm Transplantation; Neoplasms; Neovascularization, Physiologic; Polymers; Rats; Tissue Distribution | 2009 |
Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cathepsin B; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Drug Stability; Drug Synergism; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Male; Molecular Weight; Ovarian Neoplasms; Paclitaxel; Polymerization; Polymethacrylic Acids; Solubility; Technology, Pharmaceutical | 2013 |
In vitro evaluation of HPMA-copolymers targeted to HER2 expressing pancreatic tumor cells for image guided drug delivery.
Topics: Acrylamides; Animals; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrogen-Ion Concentration; Indium Radioisotopes; Inhibitory Concentration 50; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Polymers; Receptor, ErbB-2 | 2014 |
Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.
Topics: Acrylamides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts.
Topics: Acrylamides; Animals; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Polymers; Xenograft Model Antitumor Assays | 2017 |
A biocompatible and cathepsin B sensitive nanoscale system of dendritic polyHPMA-gemcitabine prodrug enhances antitumor activity markedly.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biocompatible Materials; Cathepsin B; Cell Line, Tumor; Dendrimers; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Mice; Nanostructures; Optical Imaging; Phagocytosis; Polymethacrylic Acids; Prodrugs | 2018 |